Global Minimal Residual Disease (MRD) Market Size to Reach USD 4,138.5 Million in 2030 | Emergen Research

Increasing consumer preferences for tailored therapies is a major factor driving minimal residual disease market revenue growth

Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the forecast period, according to the latest analysis by Emergen Research. Rising R&D activities and increase in research funding from various cancer institutes are major factors projected to support market revenue growth between 2021 and 2030. For instance, Invitae Corporation, based in the U.S., started a research in February 2022 to collect actual data on tailored minimal residual disease diagnostics for distinct tumor types. Inivata also introduced RaDaR assay in April 2020 to identify and track residual disease and relapse in plasma samples of patients with prior cancer diagnoses. In addition, RaDaR assay is based on next-generation sequencing platform InVision liquid biopsy, developed by Inivata, which has built-in control and error checking for highly sensitive and precise variant detection. Moreover, to improve testing and detection outcomes, companies competing in the worldwide MRD testing market are concentrating more on disease-specific and tailored diagnostic kits, which is also expected to drive revenue growth of the market.

Click the link to get a Free Sample Copy of the Report @

Identification of minimal residual diseases has become simple with development of numerous error-corrected next-generation techniques. Various error-corrected next-generation sequencing methods have been developed using molecular barcoding, based on barcoding individual DNA molecules, required to create next-generation sequencing libraries.

However, shortage of trained professionals and unavailability of centers and lack of established treatment protocols for high-value tests in emerging countries are expected to hamper revenue growth of the market. Furthermore, there is a severe lack of qualified personnel in medical field, including physicians, nurses, paramedics, and primary healthcare providers, which is also restraining revenue growth of the market.

Click to Purchase this Report at an Exclusively Discounted Rate @

Scope of Research

Report DetailsOutcome
Market Size in 2021USD 1,095.3 Million
CAGR (2021–2030)16.04%
Revenue Forecast to 2030USD  4,138.5 Million
Base Year for Estimation2021
Historical Data2019–2020
Forecast Period2022–2030
Quantitative UnitsRevenue in USD Million and CAGR in % from 2021 to 2030
Report CoverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments CoveredIndication, detection, treatment methods, treatment centers, and region
Regional ScopeNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Country ScopeU.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, and Rest of Middle East & Africa
Key Companies ProfiledAdaptive Biotechnologies, ARUP Laboratories, Bio-Rad Laboratories, Inc., Cergentis B.V., F. Hoffmann-La Roche Ltd., ICON Plc, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Mission Bio, Natera, Inc., NeoGenomics Laboratories, OPKO Health, Inc., and Sysmex Corporation
Customization Scope10 hours of free customization and expert consultation

Major Companies and Competitive Landscape

The global minimal residual disease market is consolidated with few companies accounting for majority market revenue. Major companies are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective minimal residual diseases. Some major companies included in the global minimal residual disease market report are:

  • Adaptive Biotechnologies
  • ARUP Laboratories
  • Bio-Rad Laboratories, Inc.
  • Cergentis B.V.
  • F. Hoffmann-La Roche Ltd.
  • ICON Plc
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Mission Bio
  • Natera, Inc.
  • NeoGenomics Laboratories
  • OPKO Health, Inc.
  • Sysmex Corporation

Strategic Development

  • On 06 September 2022, Tecartus (brexucabtagene autoleucel), which is a CAR T-cell therapy, has been approved by European Commission (EC) for treatment of adult patients 26 years of age and older with relapsed or refractory (r/r) B-cell precursor Acute Lymphoblastic Leukemia (ALL), according to a statement from Kite, a Gilead Company. With its clearance, Tecartus becomes first and only CAR T-cell treatment approved for this patient population, significantly filling a medical need. In addition, this is the fourth approved use of Kite cell therapy in Europe, highlighting advantages they provide to patients, particularly those with a few treatment options.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @

Some Key Highlights From the Report

  • The Polymerase Chain Reaction (PCR) segment accounted for a significant revenue share in 2021. PCR examines specific DNA segments for unusual genetic traits. The test increases DNA to make it simpler to identify and count unusual characteristics and blood cells or bone marrow can be used. PCR tests can still detect it, if there is only one cancer cell in a group of 100,000 to 1 million healthy cells.
  • The hospitals segment accounted for largest revenue share in 2021 owing to availability of various treatment options and frequent patient visits. Hospitals consistently offer services for both acute and complicated diseases, which improves and complements performance of many other parts of the healthcare system.
  • The North America market accounted for largest revenue share in 2021 owing to increasing prevalence of blood cancer and rising investments from cancer institutions. In addition, rising incidence of hematological cancers in the U.S. is increasing risk of MRD and is expected to drive revenue growth of the market in this region.

Browse Detailed Research report @

Emergen Research has segmented the global minimal residual disease market based on indication, detection, treatment methods, treatment centers, and region:

  • Indication Outlook (Revenue, USD Million; 2019–2030)
    • Leukemia
      1. Acute Lymphoblastic Leukemia (ALL)
      2. Chronic Lymphoblastic Leukemia (CLL)
      3. Acute Myeloid Leukemia (AML)
      4. Chronic Myeloid Leukemia (CML)
      5. Others
    • Lymphoma
      1. Non-Hodgkin’s Lymphoma (NHL)
      2. Marginal Zone Lymphoma
      3. Follicular Lymphoma
      4. Peripheral T-cell Lymphoma
      5. Mantle Cell Lymphoma
      6. Others
    • Multiple Myeloma (MM)
    • Solid Tumor
    • Others
  • Detection Outlook (Revenue, USD Million; 2019–2030)
    • Next-Generation Sequencing (NGS)
    • Flow Cytometry
    • Polymerase Chain Reaction (PCR)
    • Fluorescence In-Situ Hybridization (FISH)
    • Others
  • Treatment Methods Outlook (Revenue, USD Million; 2019–2030)
    • Chemotherapy
    • Stem Cell Transplant
    • CAR-T Cell Therapy
    • Others
  • Treatment Centers Outlook (Revenue, USD Million; 2019–2030)
    • Hospitals
    • Oncology Treatment Centers
    • Diagnostic Centers & Research Institutions
    • Specialty Clinics
    • Others
  • Regional Outlook (Revenue, USD Million; 2018–2030)
    • North America
      1. U.S.
      2. Canada
      3. Mexico
    • Europe
      1. Germany
      2. UK
      3. France
      4. Spain
      5. BENELUX
      6. Rest of Europe
    • Asia Pacific
      1. China
      2. India
      3. Japan
      4. South Korea
      5. Rest of APAC
    • Latin America
      1. Brazil
      2. Rest of LATAM
    • Middle East & Africa
      1. Saudi Arabia
      2. UAE
      3. Israel
      4. Rest of Middle East & Africa

Curated Reports You Shouldn't Miss: Dive In Now!

Hearing Aids Market By Type (Behind-the-ear- Hearing Aids, Receiver in-the-ear Hearing Aids, In-the-ear Hearing Aids, Canal Hearing Aids), By Hearing Loss, By Application (Adults, Pediatrics), By Distribution Channel, Forecasts to 2027

Continuous Glucose Monitoring System Market, By Component (Integrated Insulin Pumps, Transmitters & Receivers, Sensors), By Demographics (Child (≤14 years), Adult (>14 years)), By End-use (Hospitals, Clinics, Home Healthcare, Others), and By Region Forecast to 2028

Injectable Drug Delivery Market, By Device Type (Conventional Injectables, Pre-Filled Syringes, Auto-Injectors, Pen-Injectors), By Product Type (Freeze-Dried Products, Injectable Sterile Products), By End-use, and By Region Forecast to 2030

Molecular Diagnostics Market, By Product & Services (Reagent, Instrument, Software & Service), By Technology (Polymerase Chain Reaction), By Application, By End-Use, By Test Location, and By Region Forecast to 2030

Teleradiology Services Market By Imaging Technique (MRI, CT, X-Rays, Ultrasound, Mammography), By End-Users (Diagnostic Centers, Hospitals & Clinics), By Products and Services (Software, Hardware, Teleradiology services), Forecasts to 2027

Biomaterials Market By Type (Ceramic, Metallic, Polymeric, Natural, Others), By Application (Cardiovascular, Ophthalmology, Orthopedic, Plastic Surgery, Neurology, Others), and Regions Forecasts to 2027

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:

Direct Line: +1 (604) 757-9756


Explore Our Japanese Version: Minimal Residual Disease Market

Explore Our Blogs and Insights Section:

Read our Press Release @

Contact Data